bannerhome
 
 

Pipeline

PDS Biotech’s lead candidate, PDS0101, targets cancers associated with the human papillomavirus (HPV).  PDS0101 combines the utility of the Versamune® platform with a proprietary mix of HPV16 antigens, the most virulent high-risk HPV type and by far the most prevalent in patients with HPV-associated cancers.  

Approximately 43,000 patients are diagnosed with HPV-associated cancers each year, a number unlikely to be impacted in the next decade by the increased use of HPV preventive vaccines – given that the time from initial HPV infection to cancer diagnosis is often measured in decades. Nearly all of the HPV-related cancer patients that PDS0101 might treat in the coming years are already infected with HPV16.

Men and women are both impacted by HPV-associated cancers, but in strikingly different ways.  In women, HPV infection most often leads to cervical, anal or vulvar cancer.  While most men who develop HPV-associated cancer are diagnosed with oropharynx cancer, which affects the head and neck.

 

Females (24,391)

Group 74

Males (18,280)

Group 77


 

In a Phase 1 open-label, dose-ranging study, PDS0101 was evaluated for safety, tolerability and immunogenicity.  Three groups of participants – each receiving 3 doses of either 1 mg, 3 mg or 10 mg 21 days apart – were evaluated over 133 days. The study demonstrated excellent translation of the mechanism of action from preclinical models to humans resulting in a unique ability to induce high levels of active tumor-targeting CD8+ killer T-cells in vivo in circulating blood within 14 days of treatment.

Based on the results of this clinical study, PDS Biotech determined that the 3 mg dosage offered the optimal mix of efficacy and safety.  As a result, this dose was selected to be used in the ongoing Phase 2 PDS0101 clinical studies.  PDS0101 was well-tolerated with toxicity limited to low-grade injection site reactions, most of which cleared within 7-10 days.  NCT Number: NCT02065973

A post-hoc retrospective analysis demonstrated observed clearance of the CIN (lesion regression) in 80% of evaluable patients with complete regression in 60% of evaluable patients across the three tested doses as early as 1-3 months after treatment.  These results were remarkably positive given that the vast majority of the treated population were infected with multiple high-risk HPV genotypes.

In partnership with Merck & Company and the National Cancer Institute (NCI) and MD Anderson Cancer Center, PDS Biotech is studying PD0101 in three Phase 2 clinical studies in advanced head and neck cancer, HPV-related advanced cancer, and cervical cancer respectively. Two of the three Phase 2 trials combine PDS0101 with the current standard of care treatment to evaluate if the addition of PDS0101 improves the efficacy of treatment.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf